Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Revenue projections:

Revenue projections for BDX
Revenue projections for BDX

Investors may react cautiously to news that BDX's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 1.049000
forwardPE 10.760698
debtToEquity 77.284000
earningsGrowth 0.286000
revenueGrowth 0.016000
grossMargins 0.467840
operatingMargins 0.133470
trailingEps 6.120000
forwardEps 13.503770

Becton, Dickinson and Company's current ratio being 1.049 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, Becton, Dickinson and Company can easily cover its immediate liabilities, reflecting solid financial health.
BDX's Forward PE ratio is in a good range, reflecting a reasonable balance between stock price and earnings. The stock is not overpriced, leaving room for growth, which suggests potential for investors looking to capitalize on future value appreciation.
BDX's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for BDX's financial growth.

Price projections:

Price projections for BDX
Price projections for BDX

The current price of BDX, relative to its projections, shows no clear risks or opportunities. This neutral assessment may encourage investors to take a cautious approach, awaiting further developments before making substantial changes.

Insider Transactions:

Insider Transactions for BDX
Insider Transactions for BDX


20 Becton, Dickinson and Company shares were sold in recent transactions, with market price at 156.77034912109374.1 buy transactions of BDX stock were completed, with market price at 151.3364715576172.BDX's current price levels are seeing more buying activity than selling, which might indicate a bullish sentiment. Investors appear to be confident, interpreting the buying trend as a sign of positive expectations for the stock's future performance.

Recommendation changes over time:

Recommendations trend for BDX
Recommendations trend for BDX


Analysts' buy bias toward Becton, Dickinson and Company suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, Becton, Dickinson and Company is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.